Cargando…

Plasma-Treated Solutions (PTS) in Cancer Therapy

SIMPLE SUMMARY: Cold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated bef...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hiromasa, Bekeschus, Sander, Yan, Dayun, Hori, Masaru, Keidar, Michael, Laroussi, Mounir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038720/
https://www.ncbi.nlm.nih.gov/pubmed/33917469
http://dx.doi.org/10.3390/cancers13071737
_version_ 1783677440738983936
author Tanaka, Hiromasa
Bekeschus, Sander
Yan, Dayun
Hori, Masaru
Keidar, Michael
Laroussi, Mounir
author_facet Tanaka, Hiromasa
Bekeschus, Sander
Yan, Dayun
Hori, Masaru
Keidar, Michael
Laroussi, Mounir
author_sort Tanaka, Hiromasa
collection PubMed
description SIMPLE SUMMARY: Cold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated beforehand using plasma processes. This review addresses the challenges and opportunities of plasma-treated solutions (PTSs) for cancer treatment. ABSTRACT: Cold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated beforehand using plasma processes. This review addresses the challenges and opportunities of plasma-treated solutions (PTSs) for cancer treatment. These PTSs include plasma-treated cell culture media in experimental research as well as clinically approved solutions such as saline and Ringer’s lactate, which, in principle, already qualify for testing in therapeutic settings. Several types of cancers were found to succumb to the toxic action of PTSs, suggesting a broad mechanism of action based on the tumor-toxic activity of ROS/RNS stored in these solutions. Moreover, it is indicated that the PTS has immuno-stimulatory properties. Two different routes of application are currently envisaged in the clinical setting. One is direct injection into the bulk tumor, and the other is lavage in patients suffering from peritoneal carcinomatosis adjuvant to standard chemotherapy. While many promising results have been achieved so far, several obstacles, such as the standardized generation of large volumes of sterile PTS, remain to be addressed.
format Online
Article
Text
id pubmed-8038720
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80387202021-04-12 Plasma-Treated Solutions (PTS) in Cancer Therapy Tanaka, Hiromasa Bekeschus, Sander Yan, Dayun Hori, Masaru Keidar, Michael Laroussi, Mounir Cancers (Basel) Review SIMPLE SUMMARY: Cold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated beforehand using plasma processes. This review addresses the challenges and opportunities of plasma-treated solutions (PTSs) for cancer treatment. ABSTRACT: Cold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated beforehand using plasma processes. This review addresses the challenges and opportunities of plasma-treated solutions (PTSs) for cancer treatment. These PTSs include plasma-treated cell culture media in experimental research as well as clinically approved solutions such as saline and Ringer’s lactate, which, in principle, already qualify for testing in therapeutic settings. Several types of cancers were found to succumb to the toxic action of PTSs, suggesting a broad mechanism of action based on the tumor-toxic activity of ROS/RNS stored in these solutions. Moreover, it is indicated that the PTS has immuno-stimulatory properties. Two different routes of application are currently envisaged in the clinical setting. One is direct injection into the bulk tumor, and the other is lavage in patients suffering from peritoneal carcinomatosis adjuvant to standard chemotherapy. While many promising results have been achieved so far, several obstacles, such as the standardized generation of large volumes of sterile PTS, remain to be addressed. MDPI 2021-04-06 /pmc/articles/PMC8038720/ /pubmed/33917469 http://dx.doi.org/10.3390/cancers13071737 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tanaka, Hiromasa
Bekeschus, Sander
Yan, Dayun
Hori, Masaru
Keidar, Michael
Laroussi, Mounir
Plasma-Treated Solutions (PTS) in Cancer Therapy
title Plasma-Treated Solutions (PTS) in Cancer Therapy
title_full Plasma-Treated Solutions (PTS) in Cancer Therapy
title_fullStr Plasma-Treated Solutions (PTS) in Cancer Therapy
title_full_unstemmed Plasma-Treated Solutions (PTS) in Cancer Therapy
title_short Plasma-Treated Solutions (PTS) in Cancer Therapy
title_sort plasma-treated solutions (pts) in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038720/
https://www.ncbi.nlm.nih.gov/pubmed/33917469
http://dx.doi.org/10.3390/cancers13071737
work_keys_str_mv AT tanakahiromasa plasmatreatedsolutionsptsincancertherapy
AT bekeschussander plasmatreatedsolutionsptsincancertherapy
AT yandayun plasmatreatedsolutionsptsincancertherapy
AT horimasaru plasmatreatedsolutionsptsincancertherapy
AT keidarmichael plasmatreatedsolutionsptsincancertherapy
AT laroussimounir plasmatreatedsolutionsptsincancertherapy